| __timestamp | CRISPR Therapeutics AG | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5114000 | 50829000 |
| Thursday, January 1, 2015 | 13403000 | 57305000 |
| Friday, January 1, 2016 | 31056000 | 116145000 |
| Sunday, January 1, 2017 | 35845000 | 159362000 |
| Monday, January 1, 2018 | 48294000 | 206366000 |
| Tuesday, January 1, 2019 | 63488000 | 228244000 |
| Wednesday, January 1, 2020 | 88208000 | 293355000 |
| Friday, January 1, 2021 | 102802000 | 401715000 |
| Saturday, January 1, 2022 | 102464000 | 459856000 |
| Sunday, January 1, 2023 | 76162000 | 542705000 |
| Monday, January 1, 2024 | 72977000 | 492128000 |
Unleashing the power of data
In the ever-evolving biotech industry, effective cost management is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Exelixis, Inc. and CRISPR Therapeutics AG from 2014 to 2023. Over this period, Exelixis, Inc. consistently outpaced CRISPR Therapeutics AG in SG&A spending, reflecting its expansive operational scale. Notably, Exelixis's SG&A expenses surged by over 900% from 2014 to 2023, peaking at approximately $543 million in 2023. In contrast, CRISPR Therapeutics AG exhibited a more moderate increase of around 1,400%, reaching about $76 million in 2023. This disparity underscores Exelixis's aggressive market strategies and larger operational footprint. As the biotech landscape continues to shift, understanding these financial dynamics offers valuable insights into each company's strategic priorities and market positioning.
Cost Management Insights: SG&A Expenses for AbbVie Inc. and Exelixis, Inc.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and CRISPR Therapeutics AG
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and CRISPR Therapeutics AG
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG
Insmed Incorporated or Exelixis, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and CRISPR Therapeutics AG
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Bausch Health Companies Inc.
Operational Costs Compared: SG&A Analysis of Exelixis, Inc. and Supernus Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Madrigal Pharmaceuticals, Inc. and CRISPR Therapeutics AG
Operational Costs Compared: SG&A Analysis of Cytokinetics, Incorporated and CRISPR Therapeutics AG
Who Optimizes SG&A Costs Better? CRISPR Therapeutics AG or Geron Corporation
CRISPR Therapeutics AG vs Mesoblast Limited: SG&A Expense Trends